Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:ABCNYSE:BTGNASDAQ:MOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCABcann GlobalC$0.00C$0.00▼C$0.00N/AN/AN/AN/ABTGB2Gold$3.08-2.2%$2.96$2.20▼$3.51$4.07B0.9321.72 million shs57.35 million shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/AReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTGB2Gold+0.16%-5.27%-0.79%+31.04%+22.34%MORMorphoSys0.00%0.00%0.00%0.00%+5.04%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABCABcann GlobalN/AN/AN/AN/AN/AN/AN/AN/ABTGB2Gold3.86 of 5 stars4.20.01.70.03.81.71.3MORMorphoSysN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCABcann Global 0.00N/AN/AN/ABTGB2Gold 2.44Hold$4.2136.77% UpsideMORMorphoSys 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BOT, BTG, ABC, and MOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2025BTGB2GoldCormarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Moderate Buy4/14/2025BTGB2GoldScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/4/2025BTGB2GoldRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$4.504/2/2025BTGB2GoldNational BanksharesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform3/31/2025BTGB2GoldCormarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold3/20/2025BTGB2GoldCIBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$3.30 ➝ $3.602/21/2025BTGB2GoldCormarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Moderate Buy2/4/2025BTGB2GoldTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCABcann GlobalN/AN/AN/AN/AN/AN/ABTGB2Gold$1.90B2.14$0.63 per share4.88$3.00 per share1.03MORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCABcann GlobalN/AN/A0.00N/AN/AN/AN/AN/AN/ABTGB2Gold$10.10M-$0.48N/A7.700.33-33.12%5.65%4.06%N/AMORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCABcann GlobalN/AN/AN/AN/AN/ABTGB2Gold$0.082.60%N/AN/A N/AMORMorphoSysN/AN/AN/AN/AN/ALatest BOT, BTG, ABC, and MOR DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/19/2025BTGB2Goldquarterly$0.025.7%3/7/20253/7/20253/20/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCABcann GlobalN/AN/AN/ABTGB2Gold0.071.831.08MORMorphoSys4.981.381.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCABcann GlobalN/ABTGB2Gold61.40%MORMorphoSys18.38%Insider OwnershipCompanyInsider OwnershipABCABcann GlobalN/ABTGB2Gold1.18%MORMorphoSys0.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCABcann GlobalN/AN/AN/ANot OptionableBTGB2Gold4,6901.32 billion1.30 billionN/AMORMorphoSys730150.62 million150.55 millionNot OptionableBOT, BTG, ABC, and MOR HeadlinesRecent News About These CompaniesEssential Thrombocythemia Market Set for Significant Growth Across 7MM | DelveInsightMarch 21, 2025 | theglobeandmail.comRoyalty Pharma targets $3B share buyback and projects 4-9% growth in 2025 portfolio receiptsFebruary 12, 2025 | seekingalpha.comVIDEO: Triplet therapy improved PFS in relapsed, refractory follicular lymphomaJanuary 15, 2025 | healio.comNovartis closing Morphosys facilities, laying off 330 workersJanuary 8, 2025 | bioworld.comSwiss pharma giant Novartis to close biotech firm MorphosysDecember 20, 2024 | swissinfo.chNovartis to shut MorphSys sites amid pelabresib delayDecember 20, 2024 | thepharmaletter.comNovartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 JobsDecember 19, 2024 | biospace.comNovartis sheds MorphoSys staff, sites after pelabresib delayDecember 19, 2024 | pharmaphorum.comNovartis shutters MorphoSys sites, lays off staffDecember 19, 2024 | finance.yahoo.comSome 330 jobs hit as Novartis closes Morphosys, WiWo reportsDecember 19, 2024 | reuters.comNovartis raises mid-term sales guidanceNovember 21, 2024 | seekingalpha.comNovartis: launch of Morphosys drug by could be 2027 or laterNovember 21, 2024 | reuters.comIdiopathic Membranous Nephropathy Market Size is estimated to grow with a significant CAGR during the study period (2020-2034).November 14, 2024 | theglobeandmail.comEagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial OfficerNovember 12, 2024 | manilatimes.netModerna said to shuffle sales leadership; Vertex records first Casgevy saleNovember 6, 2024 | biopharmadive.comTango stock plunges 28% amid pipeline updates, Q3 earnings reportNovember 6, 2024 | msn.comRegeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drugNovember 1, 2024 | biopharmadive.comSecarna Announces Appointment of Konstantin Petropoulos as Chief Executive OfficeOctober 31, 2024 | pharmiweb.comNovartis highlights overall M&A track record following MorphoSys impairmentOctober 29, 2024 | endpts.comNovartis takes $800M MorphoSys writedown mere months after closing acquisitionOctober 29, 2024 | endpts.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines4 Healthcare Stocks With Massive Gains—and More to ComeBy Sarah Horvath | March 29, 2025View 4 Healthcare Stocks With Massive Gains—and More to ComeTesla Stock Eyes Breakout With Earnings on DeckBy Sam Quirke | April 16, 2025View Tesla Stock Eyes Breakout With Earnings on Deck3 Buyable Stocks With Solid Bottoms Ready to ReboundBy Thomas Hughes | March 31, 2025View 3 Buyable Stocks With Solid Bottoms Ready to ReboundD-Wave: Multiple Use Cases Emerge Following Quantum SupremacyBy Nathan Reiff | April 1, 2025View D-Wave: Multiple Use Cases Emerge Following Quantum SupremacyAI Takes Over Search: Is Google's Dominance At Risk?By Ryan Hasson | April 7, 2025View AI Takes Over Search: Is Google's Dominance At Risk?BOT, BTG, ABC, and MOR Company DescriptionsABcann Global CVE:ABCB2Gold NYSE:BTG$3.08 -0.07 (-2.22%) Closing price 04:00 PM EasternExtended Trading$3.09 +0.01 (+0.32%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.B2Gold Corp. operates as a gold producer company. It operates the Fekola Mine in Mali, the Masbate Mine in the Philippines, and the Otjikoto Mine in Namibia. The company also has an 100% interest in the Gramalote gold project in Colombia; 24% interest in the Calibre Mining Corp.; and approximately 19% interest in BeMetals Corp. In addition, it has a portfolio of other evaluation and exploration assets in Mali and Finland. The company was incorporated in 2006 and is headquartered in Vancouver, Canada.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 04/24/2025MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
